Mass spectrometry results are associated with outcome at multiple time points
tumor
TUMOR
We used the QIP-MS for longitudinal monitoring of 480 patients with PB serum samples at baseline and at least one additional time point. Combining MS for intact immunoglobulins and free light chains, a monoclonal immunoglobulin could be identified at baseline for each patient, which allowed us to longitudinally track the respective tumor clone in all patients. An example is shown in Fig. 